Clinical trials: CDA
Insomnia
Implementing and Evaluating Computer-Based Interventions for Mental Health: Testing an Implementation Strategy for VA Outpatient Care
Internet-based self-help programs are personalized, self-guided interventions delivered over a computer, mobile device, or other Internet platform and focused on improving knowledge, awareness, or behavior change for a mental or…
- Trial name
- NCT03151083
- Testing
- Internet-based Self-help Insomnia Intervention
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Physical Activity
Social and Financial Incentives to Increase Physical Activity Among Overweight and Obese Veterans
In this randomized, controlled trial the investigators will compare the use of social and financial incentive-based interventions to increase physical activity among overweight and obese Veterans during a 12-week intervention…
- Trial name
- NCT03563027
- Testing
- Social Incentive Gamification, Support Sponsor, Financial Incentive
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- VA Office of Research and Development
Obesity, Patient Education
Teaching Obesity Treatment Options to Adult Learners Trial
Obesity is the second leading cause of death in the U.S. The treatment of obesity and its related health issues, including cardiovascular disease and diabetes, exceeds $150 billion annually.
- Conditions
- Obesity, Patient Education, Weight Loss
- Trial name
- TOTAL (NCT03856320)
- Testing
- Educational Video
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- VA Office of Research and Development
Untreated Adult Acute Myeloid Leukemia
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This randomized phase II trial studies how well guadecitabine with or without idarubicin or cladribine works in treating older patients with previously untreated acute myeloid leukemia.
- Trial name
- NCT02096055
- Testing
- Cladribine, Guadecitabine, Idarubicin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of filgrastim (granulocyte colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone, when given together with sorafenib and to see how well they…
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT02728050
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Washington
Multiple Sclerosis, Relapsing-Remitting
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
The purpose of the study is to determine if cladribine tablets are a safe and effective treatment for relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- CLARITY (NCT00213135)
- Testing
- Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg
- Volunteers
- 1,326 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously…
- Trial name
- NCT04783935
- Testing
- Mavenclad®
- Where
- 46 sites in Australia, Austria and 12 more
- Volunteers
- 219 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
CLARITY Extension Study
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY).
- Trial name
- NCT00641537
- Testing
- Cladribine
- Where
- 116 sites in United States, Australia and 29 more
- Volunteers
- 867 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Obesity
Improving Weight Management at the VA
Compared to the general public, a higher percentage of Veterans are obese or overweight with a weight-related medical condition.
- Trial name
- NCT02626819
- Testing
- MOVE! Toward Your Goals, Enhanced Usual Care
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
To evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with RMS including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis…
- Trial name
- NCT03933202
- Testing
- Cladribine Tablets
- Where
- 66 sites in United States
- Volunteers
- 291 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen…
- Trial name
- NCT03150004
- Testing
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Medical College of Wisconsin
Multiple Sclerosis
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
The purpose of the study was the evaluation of the effect of a treatment for highly-active relapsing multiple sclerosis (RMS). This was the extension study to CLARIFY MS (NCT03369665), to assess cognitive impairment and health…
- Trial name
- NCT04776213
- Testing
- Mavenclad®
- Where
- 60 sites in Austria, Czechia and 8 more
- Volunteers
- 280 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants who Have Participated in Cladribine Clinical Trials
- Trial name
- PREMIERE (NCT01013350)
- Where
- United States
- Volunteers
- 1,161 people
- Sponsor
- EMD Serono
Depression
Improving Depression Management
Depression is disabling and affects one in five Veterans. VA's Primary Care-Mental health Integration (PC-MHI) enables specialists to support medication treatment in primary care, but timely and sufficient access to psychotherapy…
- Trial name
- IDMPC (NCT05050227)
- Testing
- cCBT Enhanced Collaborative Care, Usual Care
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- VA Office of Research and Development
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
This randomized pilot trial studies how well higher or lower dose cladribine, cytarabine, and mitoxantrone work in treating medically less fit patients with newly diagnosed acute myeloid leukemia or myeloid neoplasm.
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
- Trial name
- NCT03012672
- Testing
- Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Depression
An eHealth Intervention to Increase Depression Treatment Initiation and Adherence Among Veterans Referred for Mental Health Services
Depression is the most prevalent mental health condition among VHA patients and is strongly associated with poor functioning, negative health outcomes, and suicide.
- Trial name
- NCT05990075
- Testing
- self-monitoring
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
This phase I/II trial studies the side effects and best dosing frequency of gemtuzumab ozogamicin when given in combination with granulocyte colony stimulating factor (G-CSF), cladribine, cytarabine and mitoxantrone (GCLAM) and…
- Trial name
- NCT03531918
- Testing
- Cladribine, Cytarabine, Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Fred Hutchinson Cancer Center
Cigarette Use, Alcohol Use Above Recommended Limits
Developing a Team-Delivered Intervention for Smoking and Hazardous Drinking for Primary Care Veterans With Cardiovascular Diseases
In this study, the investigators are interested in learning how patients feel about and are impacted by a new approach for the primary care team to use to talk to patients about heart disease and health behaviors.
- Conditions
- Cigarette Use, Alcohol Use Above Recommended Limits, Cardiovascular Risk Factors (e.g., Hypertension), Cardiovascular Diseases
- Trial name
- CARE (NCT05275582)
- Testing
- CARE
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Healthcare Disparities, Mental Health
Improving Patient-Provider Communication to Reduce Mental Health Disparities
The purpose of this study was to develop and pilot test an intervention to reduce mental health disparities for racially and ethnically minoritized Veterans receiving outpatient VA mental health services.
- Trial name
- PARTNER-MH (NCT04515771)
- Testing
- PARTNER-MH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects and best dose of mitoxantrone hydrochloride when given together with filgrastim, cladribine, and cytarabine and to see how well they work in treating patients with acute myeloid…
- Conditions
- Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
- Trial name
- NCT02044796
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Fred Hutchinson Cancer Center